Company profile: X4 Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of oral small molecule CXCR4 antagonists, including mavorixafor to mobilize white blood cells and improve immune function in patients with WHIM syndrome and certain chronic neutropenic disorders; runs a global Phase 3 WHIM trial with positive results and awaiting FDA approval, plus a Phase 2 trial in chronic neutropenic disorders with plans for Phase 3.
Products and services
- WHIM Syndrome Clinical Trial: A Phase 3 trial that assesses mavorixafor’s safety and efficacy in WHIM syndrome patients, demonstrates positive results, and proceeds toward FDA approval
- Mavorixafor: An oral small-molecule therapy that mobilizes white blood cells from bone marrow into circulation to enhance immune function in WHIM syndrome and certain chronic neutropenic disorders
- Chronic Neutropenic Disorders Clinical Trial: A Phase 2 study measuring mavorixafor’s safety and efficacy across chronic neutropenic disorders, with plans to advance into a Phase 3 trial
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to X4 Pharmaceuticals
Freenome
HQ: United States
Website
- Description: Provider of blood-based tests and clinical studies for early cancer detection to improve access to routine screening, including PREEMPT CRC for colorectal cancer and the PROACT LUNG study using a blood test. Runs the Vallania and Sanderson studies targeting multiple cancers, pairing real-world data with multiomics; partners with Walgreens to increase research diversity; and acquired Oncimmune Ltd to enhance its cancer detection portfolio.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Freenome company profile →
EsoBiotec
HQ: Belgium
Website
- Description: Provider of biotechnology solutions focused on the discovery of novel cancer therapies, aiming to enable the human body to fight cancer through in vivo cell engineering.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EsoBiotec company profile →
Apollomics
HQ: United States
Website
- Description: Provider of oncology biopharmaceuticals discovering and developing mono- and combination therapies to harness the immune system. Pipeline: APL-502 (PD-L1 mAb) and APL-501 (PD-1 mAb) outside mainland China; EO1001/APL-122 (small molecule) for development outside mainland China, Hong Kong and Taiwan; uproleselan/APL-106 and GMI-1687/APL-108 (E-selectin antagonists) in mainland China, Hong Kong, Macau and Taiwan; TYG100/APL-810 in Greater China and South Africa.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apollomics company profile →
Trethera
HQ: United States
Website
- Description: Provider of small-molecule therapeutics that control DNA replication and integrity, including TRE-515, an orally bioavailable inhibitor of deoxycytidine kinase (dCK) targeting the nucleotide salvage pathway to treat solid tumors and autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trethera company profile →
Lineage Cell Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage cellular therapies addressing unmet medical needs, including OpRegen for geographic atrophy secondary to age-related macular degeneration, OPC1 for spinal cord injury, ANP1 for auditory neuropathy spectrum disorders, PNC1 for photoreceptor dysfunction, RND1 hypoimmune pluripotent stem cell lines for CNS diseases, and a dendritic cell-based VAC immuno-oncology platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lineage Cell Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for X4 Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to X4 Pharmaceuticals
2.2 - Growth funds investing in similar companies to X4 Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for X4 Pharmaceuticals
4.2 - Public trading comparable groups for X4 Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →